Aurantiamide

TargetMol
Product Code: TAR-T5814
Supplier: TargetMol
CodeSizePrice
TAR-T5814-1mg1mg£205.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5814-5mg5mg£405.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5814-1mL1 mL * 10 mM (in DMSO)£512.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5814-10mg10mg£567.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5814-25mg25mg£862.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5814-50mg50mg£1,139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5814-100mg100mg£1,508.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Aurantiamide has anti-cancer, anti-inflammatory and antinociceptive activities, it may suppress the growth of malignant gliomas by blocking autophagic flux.Aurantiamide has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB, JNK and p38 pathways.
CAS:
58115-31-4
Formula:
C25H26N2O3
Molecular Weight:
402.5
Pathway:
MAPK; NF-κb
Purity:
0.98
SMILES:
OC[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1
Target:
p38 MAPK; NF-κB

References

Zhou B , Yang Z , Feng Q , et al. Aurantiamide acetate from baphicacanthus cusia root exhibits anti-inflammatory and anti-viral effects via inhibition of the NF-?B signaling pathway in Influenza A virus-infected cells[J]. Journal of Ethnopharmacology, 2017, 199:60-67. Yoon C S , Kim D C , Lee D S , et al. Anti-neuroinflammatory effect of aurantiamide acetate from the marine fungus Aspergillus sp. SF-5921: Inhibition of NF-?B and MAPK pathways in lipopolysaccharide-induced mouse BV2 microglial cells[J]. International Immunopharmacology, 2014, 23(2):568-574.